IGC Pharma, Inc. (FRA:IGS1)
Germany · Delayed Price · Currency is EUR | Market Cap | 23.08M +7.5% |
| Revenue (ttm) | 942.64K -6.5% |
| Net Income | -5.49M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.2240 |
| Previous Close | 0.2360 |
| Day's Range | 0.2240 - 0.2240 |
| 52-Week Range | 0.2080 - 0.5300 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 1, 2026 |
About IGC Pharma
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi... [Read more]
Financial Performance
In fiscal year 2025, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2024.
Financial numbers in USD Financial StatementsNews
IGC Pharma announced beta version of Agentic Harmonization Assistant
IGC Pharma (IGC) announced the beta version of its proprietary Agentic Harmonization Assistant, an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer’s and a...
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London PO...
IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial
IGC Pharma (IGC) announced that its Phase 2 Calma trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia has reached the Company’s previously disclosed target enrollment of 146 pa...
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / Ju...
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, to...
IGC Pharma adds Mount Sinai clinical site as CALMA trial advances
IGC Pharma (IGC) announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company’s Phase 2 CALMA trial evaluating…
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma,...
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company de...
IGC Pharma to present new Tau-PET biomarker research at Global Tau conference
IGC Pharma (IGC) announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington,…
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026...
IGC Pharma Quarterly report: Q1 2026
IGC Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("I...
IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial
IGC Pharma (IGC) announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s…
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE Ame...
IGC Pharma secures Colombian authorization for psilocybin research
IGC Pharma (IGC) announced that on April 9, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development faci...
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma...
IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial
IGC Pharma (IGC) announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease. This milestone rep...
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA cli...
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA...
IGC announces activation of new clinical trial sate for Phase 2 CALMA trial
IGC Pharma (IGC) announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company’s ongoing Phase 2 CALMA…
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's d...
IGC Pharma enters national media partnership with New to The Street
IGC Pharma (IGC) announced a strategic 12-part national media partnership with New to The Street. The collaboration is designed to enhance IGC Pharma’s visibility across both institutional and retail ...
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
POTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...
IGC Pharma, New to The Street launch 12-part national media partnership
New to The Street announced a strategic 12-part media partnership with IGC Pharma (IGC). The multi-faceted campaign is designed to elevate IGC Pharma’s visibility across institutional and retail inves...
IGC Pharma reports 9-month revenue $969K
Reports 9-month net loss ($4.1M) vs. ($5.9M) a year ago. “We have surpassed 70% enrollment in the Phase 2 CALMA clinical trial, marking a significant acceleration as the program advances…